Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 6
Submit an article Journal homepage
66
Views
22
CrossRef citations to date
0
Altmetric
Research Article

In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells

Jia Dong Shi Protein Design Labs, Inc., Fremont, CA, USA
,
Chuck Bullock Protein Design Labs, Inc., Fremont, CA, USA
,
William C. Hall † Pathology Associates, A Charles River Company, Federick, MD, USA
,
Valerie Wescott Protein Design Labs, Inc., Fremont, CA, USA
,
Hong Wang Protein Design Labs, Inc., Fremont, CA, USA
,
Daniel J. Levitt Protein Design Labs, Inc., Fremont, CA, USA
&
Corine K. Klingbeil Protein Design Labs, Inc., Fremont, CA, USA
 show all
Pages 1303-1312 | Published online: 01 Jul 2009

  • Maloney, D.G., Grillo-Lópex, A.J., Bodkin, D.J., While, C.A., Liles, T.M., Royston, I., Yarns, C., Rosenberg. J. and Levy, R. (1997) "IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma". Journal of Clinical Oncology 15, 3266-3274.
  • Coiffier, B., Haioun, C., Kettcrer, N. Engen, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. and Reyes, K (1998) "Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a muticenter phase II study". Blood 92, 1927-1932.
  • Piro, L., White, C.A., Grillo López, A.J., Janakiraman, N., Beck, T.M., Selander, K., Dowden, S., Czuczman, M., Lynch, J.W., Koltiz, J.K. and Jain, V. (1997) "RITUXAN" (rituximab. IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma [abstract]". Blood 90(510a), 2272.
  • McLaughlin, P., Grillo-López, A.J., Link, BK., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I. White, C.A., Cabanillas, F, Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. and Dallaire, B K. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program". Journal of Clinical Oncology 16, 2825-2833.
  • Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y. Catovsky, D. and Mellstedl, H. (1997) "Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia". Journal of Clinical Oncoloy 15, 1567-1574.
  • Shin,. L.B., Lu, H.H., Xuan, H. and Goldenberg, D.M. (1994) "Internalization and intracellular processing of an anti-B-cell lymphoraa monoclonal antibody, LL2". International Journal of Cancer 56, 538-545.
  • Truman, J.P., Choqueux, C., Charron, D. and Mooney, N. (1996). HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways, 172. pp. 149-157.
  • Garban, F., Truman, J.P., Lord, J., Drenou, B., Plumas, J., Jacob, M.C., Sotto, J., Charron, D. and Mooney, N. (1998) "The overlooked "neoclassical" functions of major histocompatibility complex (MHC) class 11 antigens in immune and nonimmune cells". Experimental Hematology 26, 874-884.
  • Altomonte, M., Pucillo, C. and Mata, M. (1999) "Signal trausduclion via human leucocyte antigen class II molecules distinguishes between cord blood, normal, and malignant adult B lymphocytes". Journal of Cellular Physiology 179, 251-256.
  • Elsässer, D., Valerius, T., Repp, R., Weiner, G.J., Deo, V., Kalden, J.R,. van de Winkel, J.G.J., Stevenson, G.T., Glennie, M.J. and Gramatzki, M. (1996) "HLA class II as potential target antigen on malignant B cells for therapy with hispectfic antibodies in combination with granulocyie colony-stimulating factor". Blood 87, 3803-3812.
  • Epstein, A.L., Marder, R.J., Winter, J.N., Stathopoulos, E., Chen, EM., Parker, J.W. and Taylor, C.R. (1987) "Two new monoclonal antibodies, Lym-1 and l.ym-2. reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential". Cancer Research 47, 830-840.
  • Kostelny, S.A., Link, B.K., Tso, J.Y. Vasquez, M., Jorgensen, B.H., Wang, H., Hall, W.C. and Weiner, G.J. (2001) "Humanization and characterization of the anti-HLA-DR antibody ID10", International Journal of Cancer 93, 556-565.
  • Byrd, J.C., Shinn, C.A., Pearson, M.D., Flinn, I.W., Link, B.K., Wang, H., Weiner, G. and Grever, M.R (1999) "HulD10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells (CLL) independent of compliment mediated lysis but requires F-y receptor ligalion [abstract]". Blood 94(314a), 1405.
  • Green, J.M. and Tso, J.Y. (2000) "Rapid redistribution of HLA-DR to membrane rafts induced by humanized mAb ID10 results in apoptosis of B-cell lymphomas [abstract]". Blood 96(133a), 573.
  • Gingrich, S.D., Dahle, C.E., Hoskins, K.E and Seuneff. M.J. (1990) "Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes". Blood 75, 2375-2387.
  • Rose, L.M., Gunasekera, A.H., DeNardo, S.J., DeNardo, G.L. and Meares, C.F. (1996) "Lymphoma-selective antibody Lym-1 recognizes a discontinuous epilope on the light chain of HLADR10". Cancer Immunology. Immunotherapy 43, 26-30.
  • Weiner, G.J., Hall, W.C., Wang, H. and Link, B. K. (2000) "Analysis of ID10 antigen expression in malignant tissues: implications for clinical use of HuID1O (humanized monoclonal antibody) [abstract]", Journal of Immunotherapy 23, 604.
  • Stockmeyer, B., Dechant, M., Repp, R., Kalden, JR., Gramatzki, M. and Valerius, T. (2000). Enhanced killing of B lymphoma cells by G-OSF-primed effector cells and HuID10. a humanized antibody against a HLA class II glycosylation variant [poster]. The American Society of Hematology 42nd Annual Meeting and Exposition. San Francisco, CA. poster 571. December 1-5 2000.
  • Stockmeyer, B., Dechant. M., Repp, R., Kalden, J.R., Gramatzki, M. and Valerius, T. (2000) "Enhanced killing of B lymphoma cells by G-CSF-primed effector cells and HuIDlO--a humanized antibody against a HLA class II glycosylation variant [abstract]". Blood 96(132a), 571.
  • Wagner, J.G. (1976) "Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data", Journal of Pharmacokinetics and Biopharmaceutics 4, 443-467.
  • Gibaidi, M. and Perner, D. (1982) PharmacoKinetics. 2nd Ed (Marcel Dekker. New York).
  • Fuleihan, R., Spertini, F., Geha, R.S. and Chatila, T. (1992) "Role of protein kinase activation in the induction of B-cell adhesion by MHV class II ligands", Journal of Immunology 149, 1853-1858.
  • Kansas, G.S. and Tedder, T.F. (1991) "Transmembrane signals generated through MHC class II. CD19. CD20. CD39. and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependenl pathway". Journal of Immunology 147, 4094-4102.
  • Shan, D., Ledbetter, J.A. and Press, D.W. (1998) "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies". Blood 91, 1644-1652.
  • Taji, H., Kagami, Y. Okada, Y. Andou, M., Nishi, Y. Saito, H., Seto, M. and Morishima, Y. (1998) "Growth inhibition of CD20-positive B lymphoma cell lines by IDF.C-C2B8 anti-CD20 monoclonal antibody". Japanese Journal of Cancer Research 89. 748-756.
  • Vuist, W.M., Levy, R. and Maloney, D.G. (1994) "Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein", Blood 83, 899-906.
  • Leveille, C., Zckki, H., AJ-Daccak, R. and Mourad, W. (1999) "CD40- and HLA-DR-medialed cell death pathways share a lot of similarities but differ in their use of ADP-ribosyltransferase activities", International Immunology 11, 719-730.
  • Mongini, P.K., Liu, Q., Vilensky, M.A., Highet, P.F. and Inman, J. K. (1998) "Evidence for an upper affinity threshold for anti-IgMinduced apoptosis in a human B-cell lymphoma". Blood 92, 3756-4771.
  • Carpenter, P.A., Pavlovic, S., Tso, J.Y., Press, O.W., Gooley, T., Yu, X.Z. and Anasetti, C. (2000) "Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells". Journal of Immunology 165. 6205-6213.
  • Brown, Jr., P.S., Parenteeu, G.L., Dirbuj, F.M., Garsia, R.J., Goldman, C.K., Bukowski, M.A., Junghans, R.P., Queen, C., Hakimi, J. and Benjamin, W.R. (1991) "Aoti-Tac-H. a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival". Proceedings of the National Academy of Sciences of the United States of America 88, 2663-2667.
  • Reimann, K.A., Lin, W., Bixler, S., Browning, B., Ehrenfels, B.N., Lucci, J., Miatkowski, K., Olson, D., Parish, T.H., Rosa, M.D., Oleson, F.B., Hsu, Y.M., Padlan, E.A., Letvin, N.L. and Burkly, U.C. (1997) "A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties". AIDS Research and Human Retorviruses 13, 933-943.
  • Hsu, D.H., Shi, J.D., Homola, M., Rowell, T.J., Moran, J., Levin, D., Druilhet, B., Chinn, J., Bullock, C. and Klingbeil, C. (1999) "A humanized anti-CD3 antibody. HuM291. with low mitogenic activity, mediates complete and reversible T-cell deptetinn in chimpanzees", Transplantation 68, 545-554.
  • Davies, B. and Morris, T. (1993) "Physiological parameters in laboratory animals and humans". Pharmaceutical Research 10. 1093-1095.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.